Market speculation and M&A chatter have periodically surfaced regarding TG Therapeutics (TGTX), driven by unverified financial blog alerts suggesting potential interest from larger U.S.-listed biopharmaceutical acquirers seeking to add its commercial-stage multiple sclerosis portfolio and pipeline assets. While such acquisition rumors frequently trigger short-term spikes in share trading volume and stock price volatility, investors typically treat unconfirmed reports with caution until formal corporate disclosures are made.